|Title||Presenting Author/Type||Date/Time (CEST)||Location/Session|
|ARISTOTLE Biomarker Analyses|
|Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial Session: Posters Sessions||Asberg, S./ Poster||31 Aug 14:00 - 18:00||Poster area - Central Village|
|A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score Session: Prediction and Prevention of Atrial fibrillation (AF)||Hijazi, Z./ Moderated Poster||31 Aug 15:38 - 15:47||Moderated poster corner- Central Village|
|The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment Session: Atrial Fibrillation: How to improve prognosis?||Christersson, C./ Abstract Session||2 Sep 08:45 - 09:00||Tbilisi - Village 7|
|Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation Session: Posters Sessions||Aulin, J./ Poster||2 Sep 14:00 - 18:00||Poster area - Central Village|
|AMPLIFY and AMPLIFY-EXT|
|Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial Session: Posters Sessions||Agnelli, G./ Poster||2 Sep 08:30 - 12:30||Poster area - Central Village|
|Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial Session: Refining antithrombotic therapy in coronary artery disease||Cohen, A./ Moderated Poster||31 Aug 10:00 - 10:08||Moderated poster corner - Central Village|
|Predictors of hospitalization during extended treatment of venous thromboembolism in the AMPLIFY-EXT trial Session: Acute Pulmonary Embolism||Cohen, A/ Oral||30 Aug 11:18 - 11:36||Cairo Village|
|Indirect Treatment Comparisons and Economic Value Analyses|
|Efficacy and safety of apixaban versus edoxaban for stroke prevention in NVAF patients: an indirect treatment analysis Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use||Lip GYH/ Oral||2 Sep 11:00 - 11:15||Vilinius Village|
|Potential impact of apixaban on formulary budget and clinical outcomes in non-valvular atrial fibrillation patients Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use||Kachroo, S./ Oral||2 Sep 11:30 - 11:45||Vilinius Village|
|Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation Session: Posters Sessions||Lip GYH/ Poster||2 Sep 14:00 - 18:00||Central Village|
|Comparison of apixaban, dabigatran and rivaroxaban in the acute treatment and prevention of venous thromboembolism: systematic review and network meta-analysis Session: Venous Thromboembolism: What’s New||Cohen, A./ Oral||2 Sep 17:15 - 17:30||Tbilisi Village|
|Cost-effectiveness of apixaban compared to other anticoagulants for the acute (6-month) treatment of venous thromboembolism Session: Venous Thromboembolism: What’s New||Lanitis, T./ Oral||2 Sep 16:45 - 17:00||Tbilisi Village|
|Real World Data Analyses|
|Real world discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tell of first 200 days Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use||Phatak, H./ Oral||2 Sep 12:15 - 12:30||Vilinius Village|
|Warfarin discontinuation in patients with unprovoked venous thromboembolism: a large U.S. insurance database analysis Session: Posters Sessions||Liu JXC/ Poster||2 Sep 8:30 to 12:00||Central Village|
- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (apixaban) (e.g., anaphylactic reactions)
- Increased Risk of Stroke with Discontinuation of ELIQUIS in Patients with Nonvalvular Atrial Fibrillation: Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in patients with nonvalvular atrial fibrillation. If ELIQUIS must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.
- Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal bleeding. Concomitant use of drugs affecting hemostasis increases the risk of bleeding including aspirin and other anti-platelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs. Patients should be made aware of signs or symptoms of blood loss and instructed to immediately report to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
- There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). A specific antidote for ELIQUIS is not available. Hemodialysis does not appear to have a substantial impact on apixaban exposure. Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is neither scientific rationale for reversal nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban. Use of procoagulant reversal agents such as prothrombin complex concentrate, activated prothrombin complex concentrate, or recombinant factor VIIa may be considered but has not been evaluated in clinical studies. Activated charcoal reduces absorption of apixaban thereby lowering apixaban plasma concentrations.
- Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.